High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
about
Spinal cord injury: a review of current therapy, future treatments, and basic science frontiersWho is going to walk? A review of the factors influencing walking recovery after spinal cord injury.Penetrating spinal injury with wooden fragments causing cauda equina syndrome: case report and literature review.Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord.Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.Nanomedicine for treating spinal cord injury.The potential dangers of treating head injury patients with corticosteroids.Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord.Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations.Biomaterials for the central nervous systemRole of electrical stimulation for rehabilitation and regeneration after spinal cord injury: an overview.Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injuryGlucocorticoids increase skeletal muscle NF-κB inducing kinase (NIK): links to muscle atrophy.Bench-to-bedside review: Diaphragm muscle function in disuse and acute high-dose corticosteroid treatment.Biomedical applications of functionalized fullerene-based nanomaterials.Zonisamide-loaded triblock copolymer nanomicelles as a novel drug delivery system for the treatment of acute spinal cord injuryNeural plasticity and functional recovery of human central nervous system with special reference to spinal cord injury.Steroid myopathy: some unresolved issues.Pharmacological therapy for acute spinal cord injury.Methylprednisolone for the treatment of acute spinal cord injury: point.From demyelination to remyelination: the road toward therapies for spinal cord injury.Corticosteroid use in neuro-oncology: an update.Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles.Efficacy of N-acetylcysteine on neuroclinical, biochemical, and histopathological parameters in experimental spinal cord trauma: comparison with methylprednisolone.Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury.Testosterone reduced methylprednisolone-induced muscle atrophy in spinal cord-injured rats.Clinical trials in spinal cord injury: lessons learned on the path to translation. The 2011 International Spinal Cord Society Sir Ludwig Guttmann Lecture.Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.Multifunctional nanoparticles for gene delivery and spinal cord injury.Interactive effects of corticosteroid and mechanical ventilation on diaphragm muscle function.Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents?The administration of high-dose methylprednisolone for 24 h reduced muscle size and increased atrophy-related gene expression in spinal cord-injured rats.Carvedilol promotes neurological function, reduces bone loss and attenuates cell damage after acute spinal cord injury in rats.Cell Transplantation for Spinal Cord Injury: Tumorigenicity of Induced Pluripotent Stem Cell-Derived Neural Stem/Progenitor Cells.
P2860
Q27025166-3EAB3FE6-3C43-4D69-9635-105C44E3719EQ27693254-722A4EC1-EC9C-4139-945E-490E97BFE947Q30493629-77667EC5-55FB-482C-823D-E9010C19B622Q33653678-F5818878-67A6-41D9-A01A-6C6CA6901763Q34132516-29744932-4CA9-4629-BF71-19DE712F8294Q35216746-BA7A4D5C-AA0A-40B6-AABB-6DFC52CE55BCQ36300003-8EE3020F-637B-4A0E-B933-A3A2A5E0BCA3Q36633104-29CAD80A-8D84-4388-BD86-DDA102F21865Q36672603-AB2C52B9-069E-463F-A51C-48C5F4BB0B68Q36777653-23653C80-DC2C-47ED-A130-C0BE23DBA3D3Q36856898-A7665673-0959-4961-B6C3-7BBA5B1A4675Q37183229-0AC5BC0E-780E-42C2-AB05-2EDE91437EA7Q37419006-7E0B9962-A5E3-4766-A720-A74A39351B2DQ37442995-9E14F379-E570-42FB-84A2-E06DD2A465F2Q37461946-71261F69-44E1-4D23-BFF3-C5DA810D4735Q37739993-F2BEAE71-DC44-4FA0-AEA0-C2D0DFB16A78Q37799531-17B52742-EF43-4D1B-9983-F0023F32D699Q37890215-0B49B24D-0CEE-41E7-BB55-170BDD312CF4Q38082348-6B7A5D7D-155D-4256-866D-F831F5D7AAF2Q38230513-DBE2486E-C089-4FD7-A1EA-5FCF903067D1Q38366783-3E10C6FD-0250-43F9-8A5D-D92B176A62C8Q38512587-BAF651B4-C7D5-4E38-8AC0-775C830909E5Q38976812-C179B5FC-B013-4AA6-A080-EB29D6D5CEC3Q40055114-158E266B-F2BE-4801-902A-0483F011A0A3Q41783608-80D29825-E11E-4EA0-AB6F-23F75B361B9BQ42726736-7FE11690-E6B1-4FA0-8080-684B994C799CQ43863012-E82E30DE-207A-4C8A-BAC6-25314A06E19DQ44453411-1E9BE0A3-BF83-4D69-8C42-6AB9936B99E8Q45875230-4AB7B733-ABBC-41A9-A16C-0698E85ECA95Q46395889-73AE6AC4-6506-429D-B106-CD5522F34B02Q46711709-24DA5483-018F-4CFA-A006-E4C8B5D93A01Q47384308-D8F8CC10-FAF6-435C-B896-1C3DF12667D7Q51032708-F3FC24FF-74F7-4617-8A78-058D20E4E682Q55011044-107E9B46-8D64-4DC6-8CCC-9E2814DC4738
P2860
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@en
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@nl
type
label
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@en
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@nl
prefLabel
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@en
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@nl
P2093
P2860
P356
P1433
P1476
High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.SC.3101681
P577
2005-04-01T00:00:00Z
P5875
P6179
1003344787